We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

People who have two copies of certain forms or variants of the APOL1 gene are more likely to develop kidney disease. About 85 ...

Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

The NHS has launched a new genetic blood test to improve the safety of kidney donations from people of Black African and ...

Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

Genomic Variants That Increase Risk of Kidney Disease Are Found in Nearly One-Third ... having just one risk variant in a gene known as APOL1 can ... Oct. 23, 2024 — According to a study ...

Hundreds of potential kidney donors of Black African and Black Caribbean heritage can now get a simple blood test to help reduce the risk of kidney failure. The test is part of national genetic ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

MZE829 could emerge as a competitor in APOL1 kidney disease to Vertex Pharmaceuticals’ inaxaplin, which is now in Phase 3 testing. Maze said in its securities filing that preclinical models ...